title: PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer.
abstract: Regional metastatic differentiated thyroid cancer (mDTC) provides a unique model in which to study the tumor-immune interface. These lymph node metastases persist for years, generally without progression to distant metastases. Although the immune system likely impedes disease progression, it is unsuccessful in eliminating disease. Our previous studies revealed that programmed death-1 (PD-1)(+) T cells were enriched in tumor-involved lymph nodes (TILN). Tumor-associated leukocytes and tumor cells were collected from grossly involved lymph nodes from 12 patients to further characterize the phenotype and functional potential of mDTC-associated PD-1(+) T cells. PD-1(+)CD4(+) and PD-1(+)CD8(+) T cells were enriched in 8 of 12 TILN samples. PD-1(+) T cells coexpressed Tim-3 and CD69 and failed to downregulate CD27. CD8(+) T cells, but not CD4(+) T cells, from these samples were variably deficient in their ability to produce effector cytokines when compared with control TILNs that lacked resident PD-1(+) T cells. PD-1(+)CD8(+) T cells were capable of exocytosis but lacked intracellular perforin. Surprisingly, T-cell proliferative capacity was largely maintained in all samples. Thus, although PD-1 expression by mDTC-associated CD8(+) T cells was associated with dysfunction, exhaustion was not complete. Notably, molecular markers of exhaustion did not translate to dysfunction in all samples or in CD4(+) T cells. Regulatory T cells (Treg), PD-L1, and galectin-9 were commonly found in mDTC and likely contributed to the initiation of T-cell exhaustion and disease progression. Therapies that release the effects of PD-1 and Tim-3 and reduce the suppressive effects of Tregs may encourage tumor elimination in patients with mDTC.
authors.affiliation: Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
authors.forename: Jill J
authors.initials: JJ
authors.lastname: Severson
authors.affiliation: Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
authors.forename: Hilary S
authors.initials: HS
authors.lastname: Serracino
authors.affiliation: Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
authors.forename: Valerica
authors.initials: V
authors.lastname: Mateescu
authors.affiliation: Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Raeburn
authors.affiliation: Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
authors.forename: Robert C
authors.initials: RC
authors.lastname: McIntyre
authors.affiliation: Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
authors.forename: Sharon B
authors.initials: SB
authors.lastname: Sams
authors.affiliation: Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, Aurora, Colorado.
authors.forename: Bryan R
authors.initials: BR
authors.lastname: Haugen
authors.affiliation: Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. jena.french@ucdenver.edu.
authors.forename: Jena D
authors.initials: JD
authors.lastname: French
mesh_terms: D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism*; D049109:Cell Proliferation; D016207:Cytokines / Q000096:biosynthesis; D003602:Cytotoxicity, Immunologic; D005260:Female; D000072597:Hepatitis A Virus Cellular Receptor 2; D006801:Humans; D016130:Immunophenotyping; D018655:Lymphocyte Count; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010641:Phenotype; D061026:Programmed Cell Death 1 Receptor / Q000378:metabolism*; D012008:Recurrence; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D055815:Young Adult
chemical_list: D016207:Cytokines; C448908:HAVCR2 protein, human; D000072597:Hepatitis A Virus Cellular Receptor 2; D008565:Membrane Proteins; D061026:Programmed Cell Death 1 Receptor